Management of CV risk that comes with T2DM in light of novel treatment options
In his presentation, prof. Cos considered recent observations that novel classes of antidiabetic drugs can provide CV benefit in T2DM patients. Cos, Brotons and Hobbs discuss how this can improve management and outcomes of these patients.
Educational Information
This video was recorded during the two-day EPCCS CV Summit and aims to give an impression of the presentation given by prof. Cos.
Faculty
Dr. Carlos Brotons - Sant Pau Institute of Biomedical Research, Barcelona, Spain
Prof. Xavier Cos - Autonomous University of Barcelona, Barcelona, Spain. He is drector of Sant Martí Primary Health Centres (Catalonian National Health Service) Barcelona,Spain. Dr. Cos' main areas of interest are Research and Education in Primary Care with a special emphasis on the Diabetes field.
Prof. Richard Hobbs - Oxford, United Kingdom. Prof Richard Hobbs is currently Professor and Head of the Department of Primary Health Care. He is the Director of the NIHR National School for Primary Care Research (2009-) and he is the chair of EPCCS.
Disclosures
This recording was independently developed under auspices of EPCCS. The views expressed in this recording are those of the individual presenters and do not necessarily reflect the views of EPCCS. No funding was obtained for the recording of this video.
Chapters
Join us
Join the Global Primary Care Cardio Network. Membership is free.
Would you like to tell us more about yourself?
Interests
We will send you an email with a link to confirm your registration.
